Courtesy of Benzinga.
Novartis, Xencor Ink $2.4 Billion Licensing Deal In Blood Cancer (Investor’s Business Daily)
Related NVS
Novartis, Xencor Ink $2.4 Billion Licensing Deal In Blood Cancer (Investor’s Business Daily)
- Xencor Inc (NASDAQ: XNCR) surged 37 percent to $17.18. The volume of Xencor shares traded was 1251 percent higher than normal. Xencor announced a strategic collaboration with Novartis AG (ADR) (NYSE: NVS). Novartis will receive ex-US rights to XmAb 14045 and XmAb 13676.
- InterContinental Hotels Group PLC (ADR) (NYSE: IHG) shares moved up 2.28 percent to $35.94. The volume of InterContinental Hotels traded was 366 percent higher than normal. InterContinental shares have dropped 27.65 percent over the past 52 weeks, while the S&P 500 index has declined 3.03 percent in the same period.
- CRH PLC (ADR) (NYSE: CRH) shares climbed 3.54 percent to $27.48. The volume of CRH shares traded was 329 percent higher than normal. CRH shares have declined 5.59 percent over the past 52 weeks, while the S&P 500 index has dropped 3.03 percent in the same period.
- Prudential Public Limited Company (ADR) (NYSE: PUK) shares rose 9.31 percent to $32.06. The volume of Prudential shares traded was 260 percent higher than normal. Prudential’s PEG ratio is 1.00.
Posted-In: volume moversNews Intraday Update Markets Movers
